9. February 2010 19:25
Solvay Pharmaceuticals Inc. (Marietta, GA, USA) was the first company in the United States to install the innovative Morphologi G3 image analysis-based particle characterization system from Malvern Instruments.
[More]
9. February 2010 08:56
A recent electronic survey of US asthma experts demonstrated the need for better access to levalbuterol, the fast-acting medicine used to treat the narrowing of airways (bronchospasm) caused by asthma, for selected patients.
[More]
9. February 2010 08:00
Research and Markets has announced the addition of Frost & Sullivan's new report "Rheumatoid Arthritis Therapeutics Market in Thailand" to their offering.
[More]
9. February 2010 07:59
Research and Markets (http://www.researchandmarkets.com/research/4bbc14/macular_oedema_d) has announced the addition of GlobalData 's new report "Macular Oedema - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering.
[More]
9. February 2010 07:49
Research and Markets has announced the addition of GlobalData 's new report "Breast Cancer - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering.
[More]
9. February 2010 07:18
Rapid developments in the pharmaceutical industry have led to a steady increase in the use and cost of "specialty" medications to treat chronic conditions such as arthritis and psoriasis.
[More]
9. February 2010 06:53
Biomarker analysis market has excellent growth potential. The 'omics' revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years. Biomarkers have a multitude of applications such as early disease detection, identifying potential drug targets, predicting patient response to medication and accelerating clinical trials. Along with its role in making personalised medicine a reality, this technology enjoys priority in terms of funding and investments.
[More]
9. February 2010 05:00
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
[More]
9. February 2010 04:54
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected launch this year for the treatment of asthma, Merck's formoterol/mometasone will garner peak year sales of more than $250 million in the United States, France, Germany, Italy, Spain and the United Kingdom.
[More]
9. February 2010 03:35
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
[More]
9. February 2010 03:13
Glaucoma patients who take medication for the condition appear to have a reduced likelihood of death, according to a report in the February issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
[More]
9. February 2010 02:10
Differences might exist in the amount of pain medicine given to Latino and white children after surgery, found a new, small study in which Latino children received 30 percent less opioid analgesics (morphine or morphine-like drugs) than white children did.
[More]
9. February 2010 01:37
Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules. Commercial shipments of the product have already commenced.
[More]
9. February 2010 01:08
Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has received FDA approval of labetalol hydrochloride (HCl) injection, USP, commonly used to control severe hypertension. The product will be available in two vial sizes – 100 mg per 20 mL and 200 mg per 40 mL, multi-dose vials.
[More]
9. February 2010 00:40
An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition. That is the conclusion of a study published today in the Archives of Neurology.
[More]